BioCentury
ARTICLE | Company News

Paladin, Triton Pharma deal

January 20, 2014 8:00 AM UTC

Paladin acquired fellow specialty pharma Triton for an undisclosed amount. Paladin said it expects Triton to contribute sales of about C$4 million ($3.7 million) in 2014 from its portfolio of dermatology, women's health and urology drugs. Paladin also will gain exclusive, Canadian rights to Veregen sinecatechins ointment to treat genital warts. Health Canada approved the topical formulation of polyphenols extracted from green tea leaves in September. Triton had rights to Veregen under a 2011 deal with Medigene AG (Xetra:MDG1, Martinsried, Germany), which said it expected Triton to launch the product this half (see BioCentury, April 25, 2011 & Sept. 16, 2013). ...